8-K: Inotiv Reports Strong Q4, Full-Year 2025 Financial Results

Inotiv, Inc. announced improved financial results for the fourth quarter and full fiscal year 2025, driven by revenue growth and significantly reduced operating losses.

Summary

• Revenue for Q4 FY2025 increased by 5.9% to $138.1 million compared to $130.4 million in Q4 FY2024.
• Fiscal Year 2025 revenue grew by 4.5% to $513.0 million, up from $490.7 million in FY2024.
• Operating loss for Q4 FY2025 decreased by 48.5% to $6.8 million from $13.2 million in Q4 FY2024.
• Operating loss for FY2025 decreased by 64.2% to $30.9 million from $86.4 million in FY2024.
• Consolidated net loss for Q4 FY2025 was $8.6 million, an improvement from $18.9 million in Q4 FY2024.
• Consolidated net loss for FY2025 was $68.6 million, an improvement from $108.9 million in FY2024.
• Adjusted EBITDA for Q4 FY2025 was $11.8 million (8.5% of total revenue), up from $5.4 million (4.1%) in Q4 FY2024.
• Adjusted EBITDA for FY2025 was $34.0 million (6.6% of total revenue), up from $18.2 million (3.7%) in FY2024.
• Discovery and Safety Assessment (DSA) revenue increased by 15.7% in Q4 FY2025 and 4.3% in FY2025.
• Research Models and Services (RMS) revenue increased by 0.8% in Q4 FY2025 and 4.7% in FY2025.
• The book-to-bill ratio for the DSA services business was 1.08x in Q4 FY2025 and 1.05x for FY2025.
• DSA backlog stood at $138.2 million as of September 30, 2025, an increase from $129.9 million at September 30, 2024.
• The company engaged Perella Weinberg Partners to explore potential debt refinancing alternatives.
• Two U.S. properties were sold during fiscal year 2025, with net proceeds used to repay principal on term loans.
• A cybersecurity incident occurred between approximately August 5-8, 2025, with the full operational and financial impacts still being evaluated for materiality.

Sentiment

Score: 7

Explanation: The company demonstrated significant improvements in operating loss and Adjusted EBITDA, along with strong DSA segment performance and strategic execution. However, it continues to report a net loss, has increased total debt, and is evaluating the impact of a recent cybersecurity incident, which introduces uncertainty.

Positives

• Operating loss significantly decreased by 48.5% in Q4 FY2025 to $6.8 million and by 64.2% in FY2025 to $30.9 million.
• Consolidated net loss improved to $8.6 million in Q4 FY2025 from $18.9 million in Q4 FY2024, and to $68.6 million in FY2025 from $108.9 million in FY2024.
• Adjusted EBITDA saw substantial growth, increasing to $11.8 million in Q4 FY2025 from $5.4 million in Q4 FY2024, and to $34.0 million in FY2025 from $18.2 million in FY2024.
• The Discovery and Safety Assessment (DSA) segment demonstrated robust revenue growth of 15.7% in Q4 FY2025 and a 61% increase in net awards over the prior year quarter.
• DSA book-to-bill ratios of 1.08x for Q4 FY2025 and 1.05x for FY2025 indicate strong demand and future revenue potential for services.
• DSA backlog increased to $138.2 million at September 30, 2025, from $129.9 million at September 30, 2024.
• The Research Models and Services (RMS) segment's operating income increased significantly in FY2025, partly due to the non-recurrence of a $28.5 million charge from FY2024 and a $7.6 million legal settlement received.
• Successful execution of site optimization plans, including property sales, contributed to term loan repayments.

Negatives

• The company continues to report a consolidated net loss of $8.6 million for Q4 FY2025 and $68.6 million for FY2025.
• Total debt, net of debt issuance costs, increased to $402.1 million at September 30, 2025, from $393.3 million at September 30, 2024.
• Cash used in operating activities increased to $10.5 million for FY2025 compared to $6.8 million for FY2024.
• A cybersecurity incident occurred in August 2025, and the full operational and financial impacts are still being evaluated, with potential for material impact not yet determined.
• RMS revenue growth was modest at 0.8% in Q4 FY2025.
• Interest expense increased to $15.7 million in Q4 FY2025 from $12.3 million in Q4 FY2024, and to $56.6 million in FY2025 from $46.9 million in FY2024.

Risks

• Trends in the demand for services and products, including fluctuations in research and development spending by pharmaceutical and biotechnology companies.
• Market and company-specific impacts of non-human primate supply and demand matters.
• Compliance with the Resolution Agreement and Plea Agreement and the expected impacts on the company related to the compliance plan and compliance monitor, and the expected amounts, timing, and expense treatment of cash payments and other investments thereunder.
• Ability to service substantial outstanding indebtedness and to comply or regain compliance with financial covenants.
• Current and forecasted cash position; ability to make capital expenditures, fund operations, and satisfy obligations.
• Ability to manage recurring and unusual costs.
• Ability to execute on and realize the expected benefits related to restructuring and site optimization plans.
• Expectations regarding the volume of new bookings, pre-sales, pricing, cost savings initiatives, expansion of services, operating income or losses, and liquidity.
• Ability to effectively fill recent expanded capacity or any future expansion or acquisition initiatives.
• Ability to develop and build infrastructure and teams to manage growth and projects.
• Ability to continue to retain and hire key talent.
• Ability to market services and products under its corporate name and relevant brand names.
• Ability to develop new services and products.
• Ability to negotiate amendments to the Credit Agreement or obtain waivers related to the financial covenants defined within the Credit Agreement.
• Potential outcome of litigation against the company, including any settlement and amounts accrued or recoverable.
• Ability to maintain effective data protection, privacy, and cybersecurity measures and to mitigate legal, financial, and reputational risks in the event of a cyber incident, including the 2025 Cybersecurity Incident, whose full operational and financial impacts are still being evaluated and may be material.
• Impact of macroeconomic factors, including but not limited to tariffs and trade policies.

Future Outlook

The company expects to continue executing on its financial goals, focusing on improving cash flow, margins, and client metrics. Management anticipates continued progress in strategic plans and remains committed to client satisfaction and high-quality product and service delivery. However, specific forward-looking guidance or estimates for future periods are not provided beyond these general statements.

Management Comments

• "During the fourth quarter of fiscal 2025, we continued to execute on the financial goals we outlined during our investor day in May."
• "We have continued to focus on key elements in an effort to improve our cash flow, margins and client metrics."
• "We were pleased that our revenue improved over the third quarter, and the year over year quarterly revenue increase of 5.9% was in line with our expectations."
• "We remain highly focused on client satisfaction and delivery of on-time, high quality products and services."
• "In the fourth quarter, we saw DSA revenue increase 15.7% over the prior year quarter and DSA net awards increase approximately 61% over the prior year quarter."
• "We consistently monitor operational data and client metrics to help build a strong recurring client base."
• "This quarters results demonstrate continued progress in the execution of our strategic plans."
• "We want to thank all of our employees, shareholders and partners for their support and trust."

Industry Context

Inotiv operates as a contract research organization (CRO) within the drug discovery and development sector, a market driven by R&D investments from pharmaceutical and biotechnology companies. The company's strategic focus on improving cash flow, margins, and client metrics, alongside site optimization, aligns with broader industry trends emphasizing efficiency and specialized service delivery. The strong growth in the Discovery and Safety Assessment (DSA) segment, particularly in biotherapeutic analysis, suggests Inotiv is capitalizing on high-value, growing areas within the drug development pipeline, positioning itself competitively in a dynamic market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.

Corporate Governance

Legal Proceedings

• Compliance with the Resolution Agreement and Plea Agreement related to a DOJ investigation, which resulted in a significant charge in FY2024.
• Received a legal settlement payment from Freese and Nichols, Inc. (FNI) during FY2025.

Stakeholder Impact

• Shareholders: Potential for improved returns due to reduced losses and increased profitability metrics (Adjusted EBITDA), but ongoing net losses and increased debt pose risks. The cybersecurity incident could impact reputation and financial stability.
• Employees: Management expressed gratitude for employee support, indicating continued operations and strategic focus on business improvement.
• Customers: Continued focus on client satisfaction and delivery of high-quality products and services, with strong DSA net awards and backlog suggesting sustained client engagement.
• Creditors: Engagement of financial advisors for debt refinancing indicates active management of debt obligations, which is crucial given the increased total debt and cash used in operating activities.

Next Steps

• Continue to execute on the financial goals outlined during the investor day in May.
• Maintain focus on improving cash flow, margins, and client metrics.
• Provide notifications regarding the 2025 Cybersecurity Incident in accordance with applicable legal obligations.
• Complete the evaluation of the full operational and financial impacts of the 2025 Cybersecurity Incident.
• Explore potential debt refinancing alternatives with Perella Weinberg Partners.
• Host a conference call on December 3, 2025, at 4:30 pm ET to discuss fourth quarter and fiscal year 2025 results.

Key Dates

Recommendation

While Inotiv demonstrated substantial improvements in key profitability metrics like operating loss and Adjusted EBITDA, and strong growth in its DSA segment, the company still reported a significant net loss for the full fiscal year. The increase in total debt and cash used in operating activities, coupled with the ongoing evaluation of a cybersecurity incident's material impact, introduces considerable uncertainty. The engagement of financial advisors for debt refinancing is a positive step towards managing its financial structure, but the overall financial health still requires sustained improvement. Given the mixed signals of operational progress against persistent financial challenges and new risks, a 'hold' recommendation is appropriate for investors to observe further progress on debt management, profitability, and the resolution of the cybersecurity incident before making a more definitive investment decision.

Keywords

Inotiv, NOTV, Contract Research Organization, CRO, Drug Discovery, Drug Development, Nonclinical Services, Analytical Services, Research Models, Financial Results, Earnings, Q4 2025, Fiscal Year 2025, Discovery and Safety Assessment, Research Models and Services, Adjusted EBITDA, Operating Loss, Revenue Growth, Cybersecurity Incident, Debt Refinancing, SEC Filing, 8-K